Dermata Therapeutics, Inc.

As of June 20, 2025, the technical trend has shifted to a bearish stance, supported by bearish daily moving averages, Dow Theory, and KST indicators, despite some mildly bullish signals from the MACD and significant underperformance compared to the S&P 500.

Dermata Therapeutics, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $2 million and a market cap of $4.51 million. Key financial metrics include a negative P/E ratio, no dividend yield, and a return on equity of -156.92%.

As of Jun 18, Dermata Therapeutics, Inc. has a market capitalization of 4.51 million, with net sales of 0.00 million and a net profit of -11.45 million over the last four quarters. The company reported shareholder's funds of 1.56 million and total assets of 3.53 million as of Dec 24.